Antiplatelet therapy in the elderly

Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists

David Calverley

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Antiplatelet agents including aspirin, dipyridamole, the thienopyridines, and the GPIIb/IIla antagonists have collectively demonstrated their ability to have a significant impact on the incidence of recurrent MIs, strokes, and other vascular ischemic events in the geriatric population. Low-dose aspirin also seems to be effective and safe for the primary prevention of ischemic heart disease in men considered at high risk. There is no evidence that the recommendations from these studies had increased relevance to younger adults, and the studies considering age as a variable found antiplatelet agents had either similar or increased benefit in older patients. In view of the relatively reduced adverse effects of these agents when compared with their potential therapeutic benefit, it is important that they be considered in all older patients for secondary prevention and in certain high-risk groups for primary prevention of cardiovascular morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)31-48
Number of pages18
JournalClinics in Geriatric Medicine
Volume17
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

clopidogrel
Integrin beta3
Ticlopidine
Platelet Aggregation Inhibitors
Primary Prevention
Aspirin
Thienopyridines
Dipyridamole
Secondary Prevention
Geriatrics
Myocardial Ischemia
Blood Vessels
Young Adult
Stroke
Morbidity
Mortality
Incidence
Therapeutics
Population

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Antiplatelet therapy in the elderly : Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. / Calverley, David.

In: Clinics in Geriatric Medicine, Vol. 17, No. 1, 2001, p. 31-48.

Research output: Contribution to journalArticle

@article{87d90bf684f1410ba63867d38a36354c,
title = "Antiplatelet therapy in the elderly: Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists",
abstract = "Antiplatelet agents including aspirin, dipyridamole, the thienopyridines, and the GPIIb/IIla antagonists have collectively demonstrated their ability to have a significant impact on the incidence of recurrent MIs, strokes, and other vascular ischemic events in the geriatric population. Low-dose aspirin also seems to be effective and safe for the primary prevention of ischemic heart disease in men considered at high risk. There is no evidence that the recommendations from these studies had increased relevance to younger adults, and the studies considering age as a variable found antiplatelet agents had either similar or increased benefit in older patients. In view of the relatively reduced adverse effects of these agents when compared with their potential therapeutic benefit, it is important that they be considered in all older patients for secondary prevention and in certain high-risk groups for primary prevention of cardiovascular morbidity and mortality.",
author = "David Calverley",
year = "2001",
language = "English (US)",
volume = "17",
pages = "31--48",
journal = "Clinics in Geriatric Medicine",
issn = "0749-0690",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Antiplatelet therapy in the elderly

T2 - Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists

AU - Calverley, David

PY - 2001

Y1 - 2001

N2 - Antiplatelet agents including aspirin, dipyridamole, the thienopyridines, and the GPIIb/IIla antagonists have collectively demonstrated their ability to have a significant impact on the incidence of recurrent MIs, strokes, and other vascular ischemic events in the geriatric population. Low-dose aspirin also seems to be effective and safe for the primary prevention of ischemic heart disease in men considered at high risk. There is no evidence that the recommendations from these studies had increased relevance to younger adults, and the studies considering age as a variable found antiplatelet agents had either similar or increased benefit in older patients. In view of the relatively reduced adverse effects of these agents when compared with their potential therapeutic benefit, it is important that they be considered in all older patients for secondary prevention and in certain high-risk groups for primary prevention of cardiovascular morbidity and mortality.

AB - Antiplatelet agents including aspirin, dipyridamole, the thienopyridines, and the GPIIb/IIla antagonists have collectively demonstrated their ability to have a significant impact on the incidence of recurrent MIs, strokes, and other vascular ischemic events in the geriatric population. Low-dose aspirin also seems to be effective and safe for the primary prevention of ischemic heart disease in men considered at high risk. There is no evidence that the recommendations from these studies had increased relevance to younger adults, and the studies considering age as a variable found antiplatelet agents had either similar or increased benefit in older patients. In view of the relatively reduced adverse effects of these agents when compared with their potential therapeutic benefit, it is important that they be considered in all older patients for secondary prevention and in certain high-risk groups for primary prevention of cardiovascular morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=0035116232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035116232&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 31

EP - 48

JO - Clinics in Geriatric Medicine

JF - Clinics in Geriatric Medicine

SN - 0749-0690

IS - 1

ER -